Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23803273 | 1.00 | BTN3A1 (0.37) | BTN3A1CYP3A4CYP2C9POLRMTDOT1L | |
| SCHEMBL23803274 | 1.00 | BTN3A1 (0.37) | BTN3A1CYP3A4CYP2C9POLRMTDOT1L | |
| SCHEMBL23803440 | 1.00 | BTN3A1 (0.37) | BTN3A1CYP3A4CYP2C9POLRMTDOT1L | |
| SCHEMBL26331170 | 0.97 | BTN3A1 (0.37) | BTN3A1CYP3A4CYP2C9POLRMT | |
| SCHEMBL26296565 | 0.95 | CYP3A4 (0.38) | BTN3A1CYP3A4CYP2C9POLRMTDOT1L | |
| SCHEMBL26276352 | 0.95 | CYP3A4 (0.38) | BTN3A1CYP3A4CYP2C9POLRMTDOT1L | |
| SCHEMBL23803248 | 0.95 | BTN3A1 (0.35) | BTN3A1CYP3A4CYP2C9POLRMTDOT1L | |
| SCHEMBL23803245 | 0.95 | BTN3A1 (0.35) | BTN3A1CYP3A4CYP2C9POLRMTDOT1L | |
| SCHEMBL23803335 | 0.95 | BTN3A1 (0.35) | BTN3A1CYP3A4CYP2C9POLRMTDOT1L | |
| SCHEMBL23819105 | 0.95 | BTN3A1 (0.35) | BTN3A1CYP3A4CYP2C9POLRMTDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767337-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | BTN3A1 4597/4885CYP3A4 435/4885CYP2C9 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.